{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T19:10:09Z","timestamp":1746472209869,"version":"3.40.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["medical-hypotheses.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.mehy.2014.10.020","type":"journal-article","created":{"date-parts":[[2014,10,28]],"date-time":"2014-10-28T23:25:48Z","timestamp":1414538748000},"page":"832-834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pentoxifylline in the management of metabolic syndrome and chronic hepatitis C"],"prefix":"10.1016","volume":"83","author":[{"given":"Amr Hany","family":"Metwally","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mehy.2014.10.020_b0005","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/jcp.2007.048363","article-title":"Clinical and laboratory diagnosis of the metabolic syndrome","volume":"61","author":"Olufadi","year":"2008","journal-title":"J Clin Pathol"},{"issue":"6","key":"10.1016\/j.mehy.2014.10.020_b0010","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.mcna.2007.06.012","article-title":"Insulin resistance as the underlying cause for the metabolic syndrome","volume":"91","author":"Danielle Lann","year":"2007","journal-title":"Med Clin North Am"},{"issue":"2","key":"10.1016\/j.mehy.2014.10.020_b0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/jhep.2002.30692","article-title":"NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome","volume":"35","author":"Chitturi","year":"2002","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.mehy.2014.10.020_b0020","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1111\/j.1572-0241.2001.04667.x","article-title":"Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease","volume":"96","author":"Willner","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.mehy.2014.10.020_b0025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/jhep.2002.30690","article-title":"Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association","volume":"35","author":"Pagano","year":"2002","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.mehy.2014.10.020_b0030","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.amjmed.2006.02.031","article-title":"Metabolic syndrome and risk of cardiovascular disease: a meta-analysis","volume":"119","author":"Galassi","year":"2006","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.mehy.2014.10.020_b0035","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1161\/ATVBAHA.107.147835","article-title":"Inflamed adipose tissue a culprit underlying the metabolic syndrome and atherosclerosis","volume":"27","author":"Gustafson","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.mehy.2014.10.020_b0040","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1210\/en.2006-0687","article-title":"Macrophage-secreted factors impair human adipogenesis: involvement of proinflammatory state in preadipocytes","volume":"148","author":"Lacasa","year":"2007","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.mehy.2014.10.020_b0045","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.physbeh.2007.10.010","article-title":"The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance","volume":"94","author":"Goossens","year":"2008","journal-title":"Physiol Behav"},{"issue":"4","key":"10.1016\/j.mehy.2014.10.020_b0050","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI118504","article-title":"The expression of TNF alpha by human muscle. Relationship to insulin resistance","volume":"97","author":"Saghizadeh","year":"1996","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.mehy.2014.10.020_b0055","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1043-2760(00)00272-1","article-title":"Potential role of TNF-\u03b1 in the pathogenesis of insulin resistance and type 2 diabetes","volume":"11","author":"Moller","year":"2000","journal-title":"Trends Endocrinol Metab"},{"issue":"6865","key":"10.1016\/j.mehy.2014.10.020_b0060","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/414821a","article-title":"New drug targets for type 2 diabetes and the metabolic syndrome","volume":"414","author":"Moller","year":"2001","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.mehy.2014.10.020_b0065","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1172\/JCI21625","article-title":"Increased oxidative stress in obesity and its impact on metabolic syndrome","volume":"114","author":"Furukawa","year":"2004","journal-title":"J Clin Invest"},{"issue":"6651","key":"10.1016\/j.mehy.2014.10.020_b0070","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/39335","article-title":"Protection from obesity-induced insulin resistance in mice lacking TNF-\u03b1 function","volume":"389","author":"Uysal","year":"1997","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.mehy.2014.10.020_b0075","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2337\/diab.43.11.1271","article-title":"Tumor necrosis factor \u03b1: a key component of the obesity-diabetes link","volume":"43","author":"Hotamisligil","year":"1994","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.mehy.2014.10.020_b0080","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-3083.2006.001761.x","article-title":"Effect of pentoxifylline on levels of pro-inflammatory cytokines during chronic hepatitis C","volume":"63","author":"Gutierrez-Reyes","year":"2006","journal-title":"Scand J Immunol"},{"issue":"1","key":"10.1016\/j.mehy.2014.10.020_b0085","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/00007890-199307000-00036","article-title":"Immune response modulation by pentoxifylline in vitro","volume":"56","author":"Tilg","year":"1993","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.mehy.2014.10.020_b0090","first-page":"83","article-title":"Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis","volume":"24","author":"Gonzalez-Gay","year":"2006","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.mehy.2014.10.020_b0095","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1749-6632.2009.05287.x","article-title":"Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-\u03b1 therapy","volume":"1193","author":"Gonzalez-Gay","year":"2010","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"10.1016\/j.mehy.2014.10.020_b0100","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/j.1572-0241.2004.40064.x","article-title":"A pilot trial of pentoxifylline in nonalcoholic steatohepatitis","volume":"99","author":"Adams","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.mehy.2014.10.020_b0105","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1111\/j.1572-0241.2004.40220.x","article-title":"Beneficial effects of tumor necrosis factor-\u03b1 inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis","volume":"99","author":"Satapathy","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.mehy.2014.10.020_b0110","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1007\/s10620-006-9723-y","article-title":"Effects of pentoxifylline on TNF-\u03b1 production by peripheral blood mononuclear cells in patients with nonalcoholic steatohepatitis","volume":"52","author":"Duman","year":"2007","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.mehy.2014.10.020_b0115","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1440-1746.2006.04756.x","article-title":"Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis","volume":"22","author":"Satapathy","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.mehy.2014.10.020_b0120","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1007\/s10620-006-9194-1","article-title":"Amelioration of steatohepatitis with pentoxifylline in a novel nonalcoholic steatohepatitis model induced by high-fat diet","volume":"52","author":"Yaln\u0131z","year":"2007","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.mehy.2014.10.020_b0125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00498562","article-title":"Effects of pentoxifylline on red blood cell deformability and blood viscosity under hyperosmolar conditions","volume":"299","author":"Leonhardt","year":"1977","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"1","key":"10.1016\/j.mehy.2014.10.020_b0130","doi-asserted-by":"crossref","first-page":"126","DOI":"10.7326\/0003-4819-102-1-126","article-title":"Pentoxifylline and intermittent claudication","volume":"102","author":"Spittell","year":"1985","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.mehy.2014.10.020_b0135","first-page":"23","article-title":"Pentoxifylline decreases serum level of adhesion molecules in atherosclerosis patients","volume":"18","author":"Mohammadpour","year":"2014","journal-title":"Iran Biomed J"},{"issue":"1","key":"10.1016\/j.mehy.2014.10.020_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/qjmed\/hci001","article-title":"TNF-\u03b1, chronic hepatitis C and diabetes: a novel triad","volume":"98","author":"Knobler","year":"2005","journal-title":"QJM"},{"issue":"3","key":"10.1016\/j.mehy.2014.10.020_b0145","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2003.11.056","article-title":"Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance","volume":"126","author":"Shintani","year":"2004","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.mehy.2014.10.020_b0150","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1053\/j.gastro.2003.08.032","article-title":"Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression","volume":"125","author":"Hui","year":"2003","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.mehy.2014.10.020_b0155","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2004.12.049","article-title":"Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients","volume":"128","author":"Romero-G\u00f3mez","year":"2005","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.mehy.2014.10.020_b0160","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1053\/gast.2000.20189","article-title":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial","volume":"119","author":"Akriviadis","year":"2000","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mehy.2014.10.020_b0165","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/gut.50.2.241","article-title":"Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis","volume":"50","author":"Raetsch","year":"2002","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.mehy.2014.10.020_b0170","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/hep.1840170320","article-title":"Pentoxifylline prevents fibrosis in an animal model and inhibits platelet-derived growth factor\u2013driven proliferation of fibroblasts","volume":"17","author":"Peterson","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.mehy.2014.10.020_b0175","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005262.pub2","article-title":"Pentoxifylline for intermittent claudication","volume":"1","author":"Salhiyyah","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.mehy.2014.10.020_b0180","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/MEG.0000000000000068","article-title":"Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies","volume":"26","author":"Zeng","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.mehy.2014.10.020_b0185","first-page":"1053","article-title":"Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials","volume":"155","author":"Hood","year":"1996","journal-title":"Can Med Assoc J"},{"issue":"4","key":"10.1016\/j.mehy.2014.10.020_b0190","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007339.pub2","article-title":"Pentoxifylline for alcoholic hepatitis","volume":"4","author":"Whitfield","year":"2009","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987714003934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987714003934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T18:37:31Z","timestamp":1746470251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987714003934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0306987714003934"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2014.10.020","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pentoxifylline in the management of metabolic syndrome and chronic hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2014.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}